Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD (PERSOMA)
Effect of Personalized Dietary and Lifestyle Feedback on Hepatic Steatosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Prospective, Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) and combined metabolic dysfunction and alcohol-associated liver disease (MetALD) are common chronic liver diseases associated with metabolic dysfunction and an increased risk of liver-related and cardiovascular complications. Lifestyle modification, particularly dietary changes and increased physical activity, represents a cornerstone of treatment. However, general lifestyle recommendations are often insufficient to achieve sustained improvements.
This prospective, randomized controlled trial aims to investigate whether personalized dietary and lifestyle feedback based on a structured questionnaire is more effective in reducing hepatic steatosis than generic lifestyle recommendations.
A total of 174 patients with MASLD or MetALD will be randomized 1:1 to receive either personalized or generic written feedback at baseline and after 2, 4, and 6 months. Changes in hepatic steatosis, assessed by the controlled attenuation parameter (CAP), will be evaluated over a six-month period.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
This is a prospective, single-center, randomized controlled trial designed to evaluate the effectiveness of personalized dietary and lifestyle feedback compared with generic recommendations in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction and alcohol-associated liver disease (MetALD).
A total of 174 adult patients with MASLD or MetALD will be randomized in a 1:1 ratio to an intervention group receiving individualized feedback based on a structured dietary and lifestyle questionnaire or a control group receiving standardized written recommendations.
Participants will complete the questionnaire at baseline and after 2, 4, and 6 months, followed by the corresponding written feedback. Clinical, anthropometric, laboratory, and non-invasive liver assessments, including vibration-controlled transient elastography (VCTE) and controlled attenuation parameter (CAP), will be performed at baseline and after six months.
The primary objective is to compare hepatic steatosis between the two groups after six months, adjusting for baseline CAP values. Secondary objectives include assessing changes in body weight, metabolic parameters, liver stiffness, dietary habits, physical activity, and health-related quality of life.
The study aims to determine whether a simple, scalable, personalized feedback approach can improve lifestyle management in patients with MASLD or MetALD.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Georg Semmler, MD PhD
- Telefonnummer: +4314040047410
- E-post: georg.semmler@meduniwien.ac.at
Studieorter
-
-
State of Vienna
-
Vienna, State of Vienna, Österrike, 1090
- Medical University of Vienna
-
Kontakt:
- Georg Semmler, MD PhD
- Telefonnummer: +4314040047410
- E-post: sld@meduniwien.ac.at
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 18-80 years.
- Controlled attenuation parameter (CAP) >248 dB/m.
- Sufficient German language proficiency to independently complete the questionnaires.
- Written informed consent to participate in the study.
Exclusion Criteria:
- Other active chronic liver disease.
- Significant alcohol consumption, defined as ≥50 g/day in women or ≥60 g/day in men.
- Pregnancy or breastfeeding.
- Type 1 diabetes mellitus.
- Initiation or dose modification of GLP-1 receptor agonists or other weight-modifying pharmacological therapies within the previous three months.
- Planned bariatric surgery during study participation.
- Severe or unstable medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of study results.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Personalized Dietary Feedback
Participants will receive personalized written dietary feedback based on their individual responses to a structured questionnaire. The feedback will include tailored recommendations regarding dietary habits. Updated personalized feedback will be provided at baseline and after 2, 4, and 6 months. |
Participants receive individualized written dietary feedback based on their responses to a structured dietary questionnaire. The feedback includes an assessment of individual dietary habits, a visual representation of dietary patterns, and personalized recommendations to improve food choices and dietary quality. Updated feedback is provided at baseline and after 2, 4, and 6 months based on repeated questionnaire assessments. |
|
Aktiv komparator: Generic Dietary Feedback
Participants will receive standardized written dietary recommendations independent of their individual questionnaire responses. Generic feedback will be provided at baseline and after 2, 4, and 6 months. |
Participants receive standardized written dietary recommendations based on general nutritional guidelines. The information is identical for all participants in the control group and is not tailored to individual dietary habits or questionnaire responses. The same generic dietary information is provided at baseline and after 2, 4, and 6 months. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Hepatic Steatosis at 6 Months, Assessed by Controlled Attenuation Parameter (CAP) Using Vibration-Controlled Transient Elastography (VCTE)
Tidsram: 6 months (baseline CAP used for adjustment).
|
Hepatic steatosis will be quantified using the controlled attenuation parameter (CAP), measured in decibels per meter (dB/m) by vibration-controlled transient elastography (VCTE). The outcome measure is the CAP value at 6 months. The between-group difference at 6 months will be evaluated using analysis of covariance (ANCOVA), with baseline CAP included as a covariate. CAP is the only measurement reported for this outcome. |
6 months (baseline CAP used for adjustment).
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Body Weight from Baseline to 6 Months
Tidsram: Baseline and 6 months
|
Body weight will be measured in kilograms (kg). Change will be calculated as body weight at 6 months minus baseline body weight. |
Baseline and 6 months
|
|
Percentage Change in Body Weight from Baseline to 6 Months
Tidsram: Baseline and 6 months
|
Percentage change in body weight will be calculated as [(body weight at 6 months - baseline body weight) / baseline body weight] × 100. |
Baseline and 6 months
|
|
Change in Waist Circumference from Baseline to 6 Months
Tidsram: Baseline and 6 months
|
Waist circumference will be measured in centimeters (cm). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Hip Circumference from Baseline to 6 Months
Tidsram: Baseline and 6 months
|
Hip circumference will be measured in centimeters (cm). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Alanine Aminotransferase (ALT) from Baseline to 6 Months
Tidsram: Baseline and 6 months
|
Serum ALT will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Aspartate Aminotransferase (AST) from Baseline to 6 Months
Tidsram: Baseline and 6 months
|
Serum AST will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Gamma-Glutamyl Transferase (GGT) from Baseline to 6 Months
Tidsram: Baseline and 6 months
|
Serum GGT will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Patient data can be shared upon reasonable request and after fulfilling all legal and data protection requirements from the EU.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .